Roundtable Discussion: Integrating Genetics, Fluid Markers & Digital Endpoints to Sharpen Trial Enrichment

• Leveraging GBA, APOE, and LRRK2 genetics alongside plasma and CSF biomarkers to refine patient stratification strategies
• Exploring how digital endpoints (motor, cognition, speech) complement fluid biomarker signals to create multidimensional risk profiles
• Discussing the practicalities of embedding composite biomarker strategies into protocol design to improve recruitment speed, reduce costs, and strengthen regulatory alignment

Speakers:

Pallavi Sachdev

Executive Director & Head of Translational Medicine & Clinical Research

Eisai